Skip to Content

In 1994, few of China’s legions of diabetics—the nation has 96.3 million today compared with 26 million in the U.S.—received regular insulin treatments. That’s when Danish drugmaker Novo Nordisk committed to tackling diabetes in China—an effort that involved training tens of thousands of physicians, educating patients, and investing in local manufacturing and R&D. The results? A 2011 research paper estimated that the efforts had saved 140,000 life-years from diabetes-related complications. Novo, meanwhile, has a 63% market share in China.

Company Info

Sector
Health Care
Industry
Pharmaceuticals
Country
Denmark
Revenues ($ millions)15,802
Company type
Public
CEO
Lars Rebien Sørensen
Websitehttp://www.novonordisk.com
Impact Segment
Public Health/Nutrition

Fortune Rankings

Fortune 500 Rank-
Fortune 500 Profile-
Most Powerful Women Rank-
Most Powerful Women Profile-
World's Greatest Leaders Rank-
World's Greatest Leaders Profile-